Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Guanfacine (Intuniv) vs Atomoxetine in Children and Adolescents With ADHD
2022-502630-71-00Phase 4Completed
- Sponsor
- Takeda
- Start
- Nov 2019
- Modality
- Small Molecules
- Countries
- 7
01
Overview
Phase 4, randomised, double-blind trial of guanfacine in attention deficit hyperactivity disorder (ADHD) (3 arms), sponsored by Takeda. Primary endpoint: Change from baseline in the CANTAB RTI task. Started Nov 2019; status: completed.
02
Drugs
guanfacine
03
Conditions
attention deficit hyperactivity disorder (ADHD)
Beyond the preview
Go deeper on 2022-502630-71-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-502630-71-00.